Jefferies Financial Group Inc. Invests $4.90 Million in Hims & Hers Health, Inc. (NYSE:HIMS)

Jefferies Financial Group Inc. acquired a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 202,630 shares of the company's stock, valued at approximately $4,900,000. Jefferies Financial Group Inc. owned 0.09% of Hims & Hers Health at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. boosted its position in shares of Hims & Hers Health by 11.1% in the fourth quarter. Vanguard Group Inc. now owns 20,257,116 shares of the company's stock worth $489,817,000 after purchasing an additional 2,020,722 shares during the period. Farallon Capital Management LLC lifted its stake in shares of Hims & Hers Health by 64,338.5% during the 4th quarter. Farallon Capital Management LLC now owns 8,377,000 shares of the company's stock valued at $202,556,000 after buying an additional 8,364,000 shares in the last quarter. Renaissance Technologies LLC lifted its stake in shares of Hims & Hers Health by 29.0% during the 4th quarter. Renaissance Technologies LLC now owns 6,951,152 shares of the company's stock valued at $168,079,000 after buying an additional 1,562,302 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in Hims & Hers Health by 192.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after buying an additional 4,145,305 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Hims & Hers Health by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 4,329,996 shares of the company's stock worth $104,724,000 after buying an additional 40,447 shares during the period. Institutional investors own 63.52% of the company's stock.

Insider Activity

In other Hims & Hers Health news, insider Irene Becklund sold 2,203 shares of the business's stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total transaction of $63,402.34. Following the completion of the transaction, the insider now owns 8,007 shares in the company, valued at $230,441.46. The trade was a 21.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Andrew Dudum sold 128,127 shares of the company's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $33.98, for a total value of $4,353,755.46. Following the transaction, the chief executive officer now directly owns 173,655 shares in the company, valued at approximately $5,900,796.90. This represents a 42.46% decrease in their position. The disclosure for this sale can be found here. Insiders sold 606,704 shares of company stock valued at $24,621,075 in the last ninety days. Insiders own 13.71% of the company's stock.

Hims & Hers Health Stock Performance

HIMS stock traded down $1.44 during trading on Tuesday, hitting $53.39. 27,217,788 shares of the company's stock traded hands, compared to its average volume of 19,641,771. Hims & Hers Health, Inc. has a 52 week low of $13.47 and a 52 week high of $72.98. The stock has a market capitalization of $11.95 billion, a price-to-earnings ratio of 121.34 and a beta of 1.84. The business has a fifty day simple moving average of $38.37 and a 200 day simple moving average of $35.38.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, beating analysts' consensus estimates of $0.12 by $0.08. The firm had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm's revenue for the quarter was up 110.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.05 EPS. Research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. TD Cowen cut Hims & Hers Health from a "buy" rating to a "hold" rating and decreased their price target for the company from $44.00 to $30.00 in a report on Tuesday, April 29th. Leerink Partners lifted their target price on Hims & Hers Health from $24.00 to $40.00 and gave the company a "market perform" rating in a research note on Tuesday, February 25th. Needham & Company LLC restated a "buy" rating and issued a $61.00 price target on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Hims & Hers Health in a report on Wednesday, May 7th. Finally, Piper Sandler reissued a "neutral" rating and issued a $39.00 target price (up previously from $35.00) on shares of Hims & Hers Health in a report on Tuesday, May 6th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, Hims & Hers Health presently has a consensus rating of "Hold" and an average price target of $37.67.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.